Global Anti-Nuclear Antibody (ANA) Testing Market 2017-2021 - Key Vendors Are Abbott Laboratories, Alere, Bio-Rad Laboratories & Thermo Fisher Scientific - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Anti-Nuclear Antibody (ANA) Testing Market 2017-2021" report to their offering.

The analysts forecast the global anti-nuclear antibody (ANA) testing market to grow at a CAGR of 7.13 % during the period 2017-2021.

Global Anti-Nuclear Antibody (ANA) Testing Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is a shift from monoplex to multiplex testing. The focus on multiplex testing is increasing, particularly in the area of IVD, owing to the increased need for effective diagnosis. Autoimmune diseases are chronic conditions that collectively affect around 5% to 8% of the US population. The individuals who develop organ-specific autoimmune disease have a high likelihood of developing additional autoimmune disorders.

One of the major drivers for this market is increased prevalence of autoimmune diseases. Autoimmune diseases can affect any organ or system in the body, with the symptoms varying among disease types. There are about 80 types of autoimmune diseases in the world.

Key vendors

  • Abbott Laboratories
  • Alere
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific

Other prominent vendors

  • Antibodies Incorporated
  • Biocom Biotech
  • Erba Diagnostics
  • F. Hoffmann-La Roche
  • HOB Diagnostics
  • HUMAN Diagnostics
  • IMMCO
  • ImmunArray
  • Phadia
  • Seramun Diagnostica
  • Trinity Biotech

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Market segmentation by end-user

Part 07: Geographical segmentation

Part 08: Decision framework

Part 09: Drivers and challenges

Part 10: Market trends

Part 11: Vendor landscape

Part 12: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/glhcbd/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diagnostics, Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diagnostics, Oncology Drugs